CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™

The objective of this study is to evaluate the safety and effectiveness of the MobiusHD
System in a prospective, randomized, double-blind, sham-controlled multi-center pivotal
study. Patients with resistant hypertension who remain uncontrolled despite pharmacologic
treatment with maximum tolerated, guideline-directed anti-hypertensive pharmacologic therapy
will be evaluated.

Inclusion Criteria:

- Mean 24 hour ambulatory systolic blood pressure ≥145 mmHg and ≤200 mmHg and stable for
at least 8 weeks on a maximally tolerated guideline directed, (JNC8) or their
equivalent when those listed are not available dosing regimen consisting of up to 5
antihypertensive medications, with a minimum required dosing regimen of an "A+C+D"
antihypertensive medication regimen, where "A" is an angiotensin-converting enzyme
Inhibitor or an angiotensin receptor blocker, "C" is a calcium channel blocker, and
"D" is a diuretic.

Exclusion Criteria:

- Inadequacy of the carotid anatomy for treatment with the MobiusHD based on carotid
angiography.